Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.52 |
| ▸ | SRC | P12931 | 6/20 | 0.50 |
| ▸ | ABL1 | P00519 | 5/20 | 0.50 |
| ▸ | HCK | P08631 | 4/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | CDK8 | P49336 | 2/20 | 0.50 |
| ▸ | BRAF | P15056 | 2/20 | 0.50 |
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | MERTK | Q12866 | 2/20 | 0.50 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.50 |
| ▸ | FES | P07332 | 2/20 | 0.50 |
| ▸ | FER | P16591 | 2/20 | 0.50 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.50 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.50 |
| ▸ | STK25 | O00506 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2777686 | 0.93 | SRC (0.52) | KDRFGFR1SRCABL1HCK | |
| SCHEMBL2777199 | 0.92 | SRC (0.54) | KDRFGFR1SRCABL1HCK | |
| SCHEMBL12972377 | 0.90 | HCK (0.55) | KDRFGFR1SRCABL1HCK | |
| SCHEMBL2777242 | 0.89 | SRC (0.50) | KDRFGFR1SRCABL1HCK | |
| SCHEMBL2776954 | 0.89 | KDR (0.51) | KDRFGFR1MAPK14BRAFMAP2K7 | |
| SCHEMBL13991086 | 0.85 | SRC (0.67) | KDRFGFR1SRCABL1HCK | |
| SCHEMBL12972367 | 0.83 | SRC (0.57) | KDRFGFR1SRCABL1HCK | |
| SCHEMBL12972402 | 0.83 | HCK (0.57) | KDRFGFR1SRCABL1HCK | |
| SCHEMBL29391327 | 0.83 | SRC (0.58) | KDRFGFR1SRCABL1HCK | |
| SCHEMBL12972358 | 0.83 | SRC (0.58) | KDRFGFR1SRCABL1HCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855215-B2 | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-12-21 | — | — | US | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | RET, ROS1, BRAF | KDR 479/4885FGFR1 915/4885SRC 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.